Hemogenyx Pharmaceuticals (LON:HEMO) Shares Down 35.6% – Here’s Why

Hemogenyx Pharmaceuticals Plc (LON:HEMO) shares fell 35.6% during trading on Tuesday . The company traded as low as GBX 192.59 ($2.48) and last traded at GBX 196.80 ($2.53). 88,716 shares traded hands during mid-day trading, an increase of 404% from the average session volume of 17,615 shares. The stock had previously closed at GBX 305.50 ($3.93).

Hemogenyx Pharmaceuticals Stock Down 35.5 %

The company has a quick ratio of 6.72, a current ratio of 4.38 and a debt-to-equity ratio of 90.87. The stock has a market cap of £7.03 million, a PE ratio of -1,008.40 and a beta of 3.14. The business has a 50 day moving average price of GBX 354.74 and a 200 day moving average price of GBX 153.82.

Hemogenyx Pharmaceuticals Company Profile

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.